García-Méndez S, Caballero-Zavala LM, García-Olivera I, Vásquez-Manuel F, Pérez-Bustamante G, Tafoya-Ramírez F

Language: Spanish
References: 20
Page: 666-670
PDF size: 280.33 Kb.

ABSTRACT

Patients with autoimmune rheumatic diseases are at increased risk for developing infections and these are associated with increased morbidity and mortality from these diseases, especially in patients with systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and autoimmune inflammatory myopathies. The objective of this paper is to address the challenges in detecting latent tuberculosis in immunosuppressed patients and the initiation of prophylactic treatment because currently there are no well-defined guidelines indicating what action to take for detection and treatment; so far the available scientific evidence is scarce and some methodological shortcomings.

REFERENCES

1. Falagas ME, Manta KG, Betsi BI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26:663-70.

2. Alarcón GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am. 2006;20:849-75.

3. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308.

4. Navarro-Zarza JE, Alvarez-Hernández E, Casasola- Vargas JC, Estrada-Castro E, Burgos-Vargas R. Prevalence of community-acquired and nosocomial infections in hospitalized patients with systemic lupus erythematosus. Lupus. 2010;19:43-8.

5. Anolik JH. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis. 2007;65:182-6.

6. Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C et al. Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol. 2008;26(Suppl 48):S67-73.

7. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012;51:1145-53.

8. Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol. 1991;18:1180-4.

9. Rojas-Serrano J, Pedroza J, Regalado J, Robledo J, Reyes E, Sifuentes-Osornio J et al. High prevalence of infections in patients with systemic lupus erythematosus and pulmonary haemorrhage. Lupus. 2008;17:295-9.

10. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Aguirre C. High risk of tuberculosis in systemic lupus erythematosus? Lupus. 2006;15:232-5.

11. Feng PH, Tan TH. Tuberculosis in patients with systemic lupus erythematosus. Ann Rheum Dis. 1982;41:11-4.

12. Hernández-Cruz B, Ponce-de-León-Rosales S, Sifuentes-Osornio J, Ponce-de-León-Garduño A, Díaz-Jouanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. Clin Exp Rheumatol. 1999;17:81-7.

13. Ponce de León D, Acevedo-Vásquez E, Sánchez- Torres A, Cucho M, Alfaro J, Perich R et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis. 2005;64:1360-1.

14. Cobanoglu N, Ozcelik U, Kalyoncu U, Ozen S, Kiraz S, Gurcan N et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis. 2007;11:1177-82.

15. Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis. 2008;67:84-90.

16. Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol. 2009;36:1876-84.

17. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J. 2009;33:586-93.

18. Shovman O, Anouk M, Vinnitsky N, Arad U, Paran D, Litinsky I et al. QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis. 2009;13:1427-32.

19. Internal Clinical Guidelines Team (UK). Tuberculosis: Prevention, Diagnosis, Management and Service Organisation. London: National Institute for Health and Care Excellence (UK); 2016. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK338750/

20. Mok MY, Lo Y, Chan TM, Wong WS, Lau CS. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. J Rheumatol. 2005;32:609-15.